Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M P LaValley

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Statistics in Medicine|November 15, 1996
Models for empirical Bayes estimators of longitudinal CD4 countsM P LaValley, V DeGruttola
Lupus|November 24, 1999
Early stopping of clinical trials in lupus and other uncommon rheumatologic diseasesM P LaValley, D T Felson
Biometrics|September 1, 1996
Nonparametric inference in factorial designs with censored dataM G Akritas, M P LaValley
Arthritis Care and Research : the Official Journal of the Arthritis Health Professions Association|March 3, 1998
Statistical and study design issues in assessing the quality and outcomes of care in rheumatic diseasesM P LaValley, J J Anderson
Arthritis and Rheumatism|August 14, 1999
The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approachS Amin, M P LaValley, R W Simms, et al.
Arthritis and Rheumatism|April 28, 2001
Use of the Americans with Disabilities Act by persons with rheumatic diseases and factors associated with useS H Allaire, S R Evans, M P LaValley, et al.
JAMA|March 25, 2000
Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysisT E McAlindon, M P LaValley, J P Gulin, et al.
Molecular Oral Microbiology|May 7, 2015
Liver X receptors contribute to periodontal pathogen-elicited inflammation and oral bone lossN Huang, Y B Shaik-Dasthagirisaheb, M P LaValley, et al.
Journal of Clinical Epidemiology|February 13, 2001
The validity of different definitions of radiographic worsening for longitudinal studies of knee osteoarthritisM P LaValley, T E McAlindon, C E Chaisson, et al.
Arthritis and Rheumatism|September 29, 1998
Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent?D T Felson, J J Anderson, M L Lange, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Statistics in Medicine|November 15, 1996
Models for empirical Bayes estimators of longitudinal CD4 countsM P LaValley, V DeGruttola
Lupus|November 24, 1999
Early stopping of clinical trials in lupus and other uncommon rheumatologic diseasesM P LaValley, D T Felson
Biometrics|September 1, 1996
Nonparametric inference in factorial designs with censored dataM G Akritas, M P LaValley
Arthritis Care and Research : the Official Journal of the Arthritis Health Professions Association|March 3, 1998
Statistical and study design issues in assessing the quality and outcomes of care in rheumatic diseasesM P LaValley, J J Anderson
Arthritis and Rheumatism|August 14, 1999
The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approachS Amin, M P LaValley, R W Simms, et al.
Arthritis and Rheumatism|April 28, 2001
Use of the Americans with Disabilities Act by persons with rheumatic diseases and factors associated with useS H Allaire, S R Evans, M P LaValley, et al.
JAMA|March 25, 2000
Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysisT E McAlindon, M P LaValley, J P Gulin, et al.
Molecular Oral Microbiology|May 7, 2015
Liver X receptors contribute to periodontal pathogen-elicited inflammation and oral bone lossN Huang, Y B Shaik-Dasthagirisaheb, M P LaValley, et al.
Journal of Clinical Epidemiology|February 13, 2001
The validity of different definitions of radiographic worsening for longitudinal studies of knee osteoarthritisM P LaValley, T E McAlindon, C E Chaisson, et al.
Arthritis and Rheumatism|September 29, 1998
Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent?D T Felson, J J Anderson, M L Lange, et al.
Pageof 2